Ayala Pharmaceuticals (NASDAQ:AYLA) announced its quarterly earnings results on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04), Fidelity Earnings reports.
Shares of AYLA opened at $10.28 on Friday. The stock’s 50-day moving average price is $12.00. Ayala Pharmaceuticals has a one year low of $8.62 and a one year high of $16.50.
A number of research analysts have recently issued reports on AYLA shares. Oppenheimer reiterated a “buy” rating and issued a $23.00 price target on shares of Ayala Pharmaceuticals in a report on Thursday, August 13th. Raymond James reissued a “buy” rating on shares of Ayala Pharmaceuticals in a research report on Thursday, August 13th. Finally, Zacks Investment Research raised Ayala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 14th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $24.00.
Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
See Also: Momentum Indicators
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.